ArticleLeukemia & lymphoma2010

Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.

Peter H O'Donnell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.